No quarterly revenue total was found in Kyverna Therapeutics, Inc.'s SEC filings.
Kyverna Therapeutics, Inc. (KYTX) files with the SEC under industry code 2836, Biological Products, (No Diagnostic Substances). Free cash flow was -$40.6 million. As of Jun 30, 2026 it held $199.4 million in cash and investments and $33.0 million in total debt.
Revenue
—
Net income
$-38.32M
+8.9% vs year-ago quarter
Operating cash flow
$-40.31M
-26.2% vs year-ago quarter
Free cash flow
$-40.60M
-27.1% vs year-ago quarter
EPS
$-0.63
+35.1% vs year-ago quarter
Dividend per share
None
Shares outstanding
61.84M
+43.0% vs year-ago quarter
Net cash
$166.43M
Q2 FY2026
Operating margin
—
Company profile
- Industry
- Biological Products, (No Diagnostic Substances) (SIC 2836)
- Listed as
- KYTX (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Emeryville, CA
- SEC filer status
- , Emerging growth company
- SEC CIK
- 1994702
- Former names
- Kyverna Therapeutics, Inc. (until Oct 19, 2026)
Other Biological Products, (No Diagnostic Substances) companies
- Amgen Inc AMGN
- Gilead Sciences, Inc. GILD
- Moderna, Inc. MRNA
- Argenx SE ARGX
- Revolution Medicines, Inc. RVMD
- Biogen Inc. BIIB
- BioNTech SE BNTX
- Exelixis, Inc. EXEL
All 182 Biological Products, (No Diagnostic Substances) companies
Key figures
Fiscal-year totals from the annual reports; switch to Annual for the full-year view. Balance sheet lines are as of each year end.
| Line | Q2 FY2026 Jun 30, 2026 |
Q1 FY2026 Mar 31, 2026 |
Q4 FY2025 Dec 31, 2025 |
Q3 FY2025 Sep 30, 2025 |
Q2 FY2025 Jun 30, 2025 |
|---|---|---|---|---|---|
| Operating income | -$39.6M | -$41.4M | -$39.3M | -$38.7M | -$44.4M |
| Net income | -$38.3M | -$39.7M | -$37.8M | -$36.8M | -$42.1M |
| Diluted EPS | -$0.63 | -$0.66 | -$0.80 | -$0.85 | -$0.97 |
| Operating cash flow | -$40.3M | -$41.6M | -$33.5M | -$43.3M | -$31.9M |
| Free cash flow | -$40.6M | — | -$33.5M | -$43.3M | -$32.0M |
| Total assets | $219.8M | $257.0M | $293.8M | $187.2M | $226.5M |
| Total liabilities | $54.3M | $61.4M | $61.5M | $35.2M | $42.1M |
| Stockholders' equity | $165.5M | $195.6M | $232.3M | $151.9M | $184.4M |
| Cash and investments | $199.4M | $236.4M | $279.3M | $171.1M | $211.7M |
| Total debt | $33.0M | $8.9M | $4.3M | $5.0M | $5.9M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Regulation FD disclosure
|
Sep 24, 2026 | Sep 24, 2026 |
| 10-Q | Quarterly report | Aug 11, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Results of operations
|
Aug 11, 2026 | Aug 11, 2026 |
| 8-K |
Current report
Material agreement, Regulation FD disclosure
|
Jul 27, 2026 | Jul 23, 2026 |
| 8-K |
Current report
Material agreement
|
Jul 9, 2026 | Jul 8, 2026 |
| 8-K |
Current report
Shareholder vote results
|
Jun 2, 2026 | May 27, 2026 |
All 187 Kyverna Therapeutics, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.